1. Home
  2. LIXT vs JAGX Comparison

LIXT vs JAGX Comparison

Compare LIXT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • JAGX
  • Stock Information
  • Founded
  • LIXT 2005
  • JAGX 2013
  • Country
  • LIXT United States
  • JAGX United States
  • Employees
  • LIXT N/A
  • JAGX N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIXT Health Care
  • JAGX Health Care
  • Exchange
  • LIXT Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • LIXT 3.0M
  • JAGX 3.5M
  • IPO Year
  • LIXT N/A
  • JAGX N/A
  • Fundamental
  • Price
  • LIXT $0.74
  • JAGX $2.58
  • Analyst Decision
  • LIXT
  • JAGX Strong Buy
  • Analyst Count
  • LIXT 0
  • JAGX 1
  • Target Price
  • LIXT N/A
  • JAGX $60.00
  • AVG Volume (30 Days)
  • LIXT 82.2K
  • JAGX 90.6K
  • Earning Date
  • LIXT 08-07-2025
  • JAGX 08-12-2025
  • Dividend Yield
  • LIXT N/A
  • JAGX N/A
  • EPS Growth
  • LIXT N/A
  • JAGX N/A
  • EPS
  • LIXT N/A
  • JAGX N/A
  • Revenue
  • LIXT N/A
  • JAGX $11,552,000.00
  • Revenue This Year
  • LIXT N/A
  • JAGX $22.41
  • Revenue Next Year
  • LIXT N/A
  • JAGX $30.00
  • P/E Ratio
  • LIXT N/A
  • JAGX N/A
  • Revenue Growth
  • LIXT N/A
  • JAGX 13.93
  • 52 Week Low
  • LIXT $0.64
  • JAGX $2.43
  • 52 Week High
  • LIXT $3.00
  • JAGX $110.75
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 30.79
  • JAGX 28.76
  • Support Level
  • LIXT $0.64
  • JAGX $2.61
  • Resistance Level
  • LIXT $0.93
  • JAGX $3.30
  • Average True Range (ATR)
  • LIXT 0.13
  • JAGX 0.28
  • MACD
  • LIXT -0.05
  • JAGX 0.06
  • Stochastic Oscillator
  • LIXT 16.99
  • JAGX 6.56

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: